NCT06741111Completed
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
Source: ClinicalTrials.gov · Last updated 22 Jun 2025
Brief summary (registry, in English)
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL) 2024 care pathway
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1233970 (actual)
- First submitted
- 16 Dec 2024
- Start date
- Jan 2025
- Primary completion date
- May 2025
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06741111
What you commit to
- Study type: Observational
- Participants enrolled: 1233970
- From Jan 2025 to the primary completion date, May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Missing value on either aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or platelet count (PLT)
Other
- Individuals originating from centers with fewer than 100 participants
- Missing value of liver stiffness measurement (LSM)
- Had an interquartile range/median ratio above or equal to 30% of the measurement of LSM
- Missing value on FPG, TG, HDLc or BP (to define the presence of metabolic risk factors)
- Missing value on abdominal ultrasound
- For EASL not at-risk population 1. People with T2D or \[obesity＋above or equal to 1 cardiometabolic risk factor(s)\] or elevated liver enzymes
- For EASL-SAFE/NFS
- 1\. Missing value on globulin
Who the study is looking for
- For All and Study population:
- Male or female, age above or equal to 18 years on health-check-up visit day
- No missing value on sex
- For EASL at risk population
- Must be part of study population.
- People with T2D or \[obesity＋above or equal to 1 cardiometabolic risk factor(s)\] or elevated liver enzymes
- For EASL not at-risk population
- 1\. Must be part of study population.
- For EASL-SAFE
- Must be part of EASL at risk population
- For AGA at risk population
- Must be part of study population.
- People with 2 or more metabolic risk factors (EASL-MASLD criteria) or T2D or steatosis on any imaging modality or with elevated aminotransferases
- For CSH MAFLD population
- Must be part of study population.
- Liver steatosis on abdominal ultrasound
- With at least one component of Metabolic syndrome (MetS \[CSH\])
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.